Latest News of IMAB
FDA grants breakthrough status to J&J's nipocalimab for SjD treatment
The FDA awarded Johnson & Johnson's nipocalimab its second breakthrough therapy designation for treating moderate-to-severe Sjögren's disease. The Phase II DAHLIAS study showed positive outcomes, lea...
Otsuka's sibeprenlimab shows promise in Phase III IgA nephropathy trial
Otsuka Pharmaceutical's Phase III trial on sibeprenlimab for IgA nephropathy showed positive interim results. The monoclonal antibody demonstrated a significant reduction in urine protein levels, meet...
GSK's depemokimab shows promise in Phase III trials for chronic rhinosinusitis
GSK's Phase III trials of depemokimab in CRSwNP patients showed significant improvements compared to placebo, meeting primary endpoints. The drug's potential as a convenient treatment option is promis...
-
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
By Yahoo! Finance | 1 month agoGSK plc announced positive results from phase 3 trials for depemokimab in treating chronic rhinosinusitis with nasal polyps. The trials met primary endpoints, showing efficacy and safety in reducing p...
-
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
By Yahoo! Finance | 2 months agoJohnson & Johnson's TAR-200 plus cetrelimab combination therapy shows promising results in reducing tumor size for patients with muscle-invasive bladder cancer, potentially improving surgical outcomes...
-
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
By Yahoo! Finance | 2 months agoJohnson & Johnson submitted a BLA to the FDA for nipocalimab, a potential treatment for generalized myasthenia gravis. Data from the Vivacity-MG3 study showed sustained disease control in gMG patients...